Andrew Huberman· PhD
I think we can assume that the cost is going to come down just as everything whole genome sequencing is is going to come down. Maybe even insurance would cover it at some point.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
I think we can assume that the cost is going to come down just as everything whole genome sequencing is is going to come down. Maybe even insurance would cover it at some point.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.